-
Clinical Oncology (Royal College of... Sep 2022
Topics: Humans; Medical Oncology; Oncologists; Physician-Patient Relations
PubMed: 35431120
DOI: 10.1016/j.clon.2022.03.018 -
Archives of Pathology & Laboratory... Dec 2019
Review
Topics: Humans; Immunotherapy; Medical Oncology; Neoplasms; Oncologists; Pathologists; Pathology, Clinical
PubMed: 31403333
DOI: 10.5858/arpa.2019-0340-SA -
The Oncologist Jul 2022Susan E. Bates reflects on the history of The Oncologist and articulates her vision for the future of the journal as she assumes the role of Editor-in-Chief.
Susan E. Bates reflects on the history of The Oncologist and articulates her vision for the future of the journal as she assumes the role of Editor-in-Chief.
Topics: Humans; Oncologists
PubMed: 35790115
DOI: 10.1093/oncolo/oyac125 -
Der Radiologe Jan 2021Modern oncology has implemented several novel modalities, which increasingly warrant interdisciplinarity, dedicated imaging methods as well as intensive communication... (Review)
Review
CLINICAL ISSUE
Modern oncology has implemented several novel modalities, which increasingly warrant interdisciplinarity, dedicated imaging methods as well as intensive communication between imager and oncologists.
STANDARD TREATMENT
The classical pillars of cancer treatment are surgery, radiotherapy, and chemotherapy.
TREATMENT INNOVATIONS
Evidence-based oncology, radio-oncology, and surgery, individualized precision oncology, novel drug classes, immuno-oncology, minimally invasive diagnostic and treatment methods.
DIAGNOSTIC WORK-UP
Standard imaging methods are undergoing constant innovation and are being supplemented by specific radiotracers that can be used for radionuclide therapy. Adapted response criteria are to be used in the context of targeted therapy or checkpoint inhibitors.
PERFORMANCE AND ACHIEVEMENT
Modern cancer treatment enables improved tumor control. Due to its complexity, however, it increasingly warrants structured reporting and intense communication between imager and oncologists, to make best use of its potential.
Topics: Humans; Medical Oncology; Neoplasms; Oncologists; Precision Medicine; Radiation Oncology
PubMed: 33340067
DOI: 10.1007/s00117-020-00790-3 -
Journal of Clinical Oncology : Official... Sep 2016
Topics: Female; Guilt; Humans; Oncologists; Physician-Patient Relations; Physicians, Women; Women, Working; Work-Life Balance
PubMed: 27400945
DOI: 10.1200/JCO.2016.67.0802 -
Annals of Surgical Oncology Dec 2022
Topics: Humans; Oncologists
PubMed: 36209327
DOI: 10.1245/s10434-022-12646-2 -
Journal of Clinical Oncology : Official... Nov 2019
Topics: Antineoplastic Agents; Attitude of Health Personnel; Chemotherapy, Adjuvant; Clinical Decision-Making; Decision Support Techniques; Evidence-Based Medicine; Health Knowledge, Attitudes, Practice; Humans; Neoplasms; Oncologists; Patient Selection; Risk Assessment; Risk Factors; Unnecessary Procedures
PubMed: 31398083
DOI: 10.1200/JCO.19.00741 -
Seminars in Hematology Oct 2017In the era of modern communication, the physician and patient relationship has evolved to include an entirely new dimension-social media. This new dimension offers... (Review)
Review
In the era of modern communication, the physician and patient relationship has evolved to include an entirely new dimension-social media. This new dimension offers several opportunities for patient education, research and its dissemination, and professional development for health care providers; it can also serve as a platform for addressing important public health issues. However, these advantages come with challenges such as threats to patient and professional privacy. In this article, we dissect the benefits and drawbacks of this social evolution on the practicing hematologist-oncologist. We also perform a review of the current literature on the integration of social media in the practice of hematology/oncology; examine available guidelines for information exchange between health care professionals, industry, pharmaceutical companies, advocacy groups, and patients; and offer ways to create its seamless integration into clinical hematology-oncology practice.
Topics: Hematology; Humans; Oncologists; Social Media
PubMed: 29153080
DOI: 10.1053/j.seminhematol.2017.07.003 -
ESMO Open Feb 2022The European Society for Medical Oncology (ESMO) 2021 conference provided a high number of randomized phase III trial reports, many of which were claimed to be practice... (Review)
Review
BACKGROUND
The European Society for Medical Oncology (ESMO) 2021 conference provided a high number of randomized phase III trial reports, many of which were claimed to be practice changing. Given the short time available for conference presentations, results and conclusions tend to have greatest priority with less time remaining for study background and study methodology.
PURPOSE
On behalf of the ESMO Practicing Oncologists Working Group, 11 potentially practice-changing reports were selected and screened for three main questions: (i) Did the investigators provide sufficient details with regard to Patients and Methods to make the results comprehensible? (ii) Were there any reasons to consider bias? (iii) To which extent did the results presented translate to clinical benefit?
RESULTS
In 2 out of 11 trials, the study design presented differed considerably from the study design described at ClinicalTrials.gov. Allocation concealment was not carried out in 6 out of 11 trials. In none of the trials reporting progression-free survival was informative censoring considered an issue. In none of the trials reporting overall survival was desirable crossover considered an issue. Defined trial outcome measures depicted at ClinicalTrials.gov, which could boost or weaken the ESMO-Magnitude of Clinical Benefit Scale score, were often lacking in the presentation. Study success was claimed in a heterogeneous manner, which was often not clearly linked to overall clinical benefit.
CONCLUSION
ESMO conference presentations can inform the scientific community and catalyze further research but cannot replace the full papers in peer-reviewed journals, which are needed to estimate the thoroughness of the results, the overall impact on clinical benefit and the consequences for future treatment guidelines.
Topics: Clinical Trials, Phase III as Topic; Humans; Medical Oncology; Neoplasms; Oncologists; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Research Design
PubMed: 35051788
DOI: 10.1016/j.esmoop.2021.100376 -
Surgical Oncology Clinics of North... Jul 2020Wounds resulting from wide local excision of melanoma vary in size and complexity, and require individualized solutions to achieve satisfactory closure. Goals of... (Review)
Review
Wounds resulting from wide local excision of melanoma vary in size and complexity, and require individualized solutions to achieve satisfactory closure. Goals of reconstruction include restoration of form, function, and aesthetics while minimizing donor site morbidity without compromising the effectiveness and safety of oncologic melanoma treatment. Optimal reconstruction relies on an in-depth understanding of the defect, locoregional anatomy and vasculature, available donor tissues, and basic wound healing and surgical principles. This article provides a broad overview of preoperative patient, timing, and wound considerations; various surgical techniques for complex reconstruction throughout the body; and postoperative care and complication management.
Topics: Humans; Melanoma; Oncologists; Plastic Surgery Procedures; Skin Neoplasms
PubMed: 32482313
DOI: 10.1016/j.soc.2020.02.003